Piascledin® 300 Efficacy in the Management of Osteoarthritis: Proved in Clinical Trials, Confirmed by European Practice

O.P. Bortkevych

Abstract


The problem of osteoarthritis management and its new approaches are discussed in the article. The new SYSADOA preparation Piascledin® 300, which had been used worldwide for hip and knee osteoarthritis, has appeared in Ukraine. European evidence based data for Piascledin® 300 efficacy and advantages of its admi-nistration are presented in the article.


Keywords


osteoarthritis; Piascledin® 300; cytokines; transfor-ming growth factor; clinical trials

References


www.rheumatology.kiev.ua




DOI: https://doi.org/10.22141/1608-1706.4.17.2016.77490

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru